# Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Source: https://onco.cc/trials/nct06947967/  
OnCo record `nct06947967` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cyclophosphamide, Doxorubicin, Prednisone and Vincristine in non-Hodgkin lymphoma, run by Chipscreen Biosciences, Ltd., now recruiting.

## Summary

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype is a phase 3 interventional study registered as NCT06947967 by Chipscreen Biosciences, Ltd., with 224 participants planned, started 2025-08-12 and due to reach its primary completion in 2032-12. Interventions recorded: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06947967
- Phase: 3
- Setting: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)
- Sponsor: Chipscreen Biosciences, Ltd.
- Enrolled: 224

## Sources

- ClinicalTrials.gov NCT06947967: https://clinicaltrials.gov/study/NCT06947967

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Prednisone](https://onco.cc/drugs/prednisone/), [Vincristine](https://onco.cc/drugs/vincristine/)
- companies: [Chipscreen Biosciences](https://onco.cc/companies/chipscreen/)

---
JSON: https://onco.cc/api/v1/entities/nct06947967.json